Literature DB >> 1003551

Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines.

I J Fidler, G L Nicolson.   

Abstract

The fate of bloodborne malignant melanoma cells selected for their enhanced ability to form lung colonies was examined to determine how specific tumor cells are arrested in certain organs during the experimental metastasis process. After murine B16 melanoma variant tumor cell lines with low (B16-F1) or high (B16-F10) survival and growth potential in vivo were admisistered by iv or intracardiac injections into syngeneic C57BL/6 mice, the quantitative distribution of [125l]5-iodo-2'-deoxyuridine (125IUDR)-labeled cells in the organs and subsequent formation of metastatic lung colonies were assessed. The initial distribution of viable tumor cells was dependent on the route of injection: Soon after iv injection, more 125IUDR-labeled B16 cells were localized in the lungs and fewer in the blood and other organs than after intracardiac injection. However, 1 day after the injection, the number of viable tumor cells in the lungs was independent of the route of injection, and at 14 days the quantity of resulting lung tumor colonies was similar. Variant line B16-F10 cells were better arrested and formed more tumors per input cell than B16-F1, regardless of the injection route. B16-F10 yielded only lung tumor colonies, whereas B16-F1 formed some extrapulmonary tumor growths. The results suggested that the ultimate fate of circulating tumor cells was not determined solely by nonspecific arrest in the capillary bed of the first organ encountered, and that in vivo selection could produce tumor line variants with organs preferences.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003551     DOI: 10.1093/jnci/57.5.1199

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  96 in total

1.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.

Authors:  Lixia Guo; Dominic Fan; Fahao Zhang; Janet E Price; Ju-Seog Lee; Dario Marchetti; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.

Authors:  Yogesh M Kulkarni; Emily Chambers; A J Robert McGray; Jason S Ware; Jonathan L Bramson; David J Klinke
Journal:  Integr Biol (Camb)       Date:  2012-07-09       Impact factor: 2.192

3.  Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation.

Authors:  Satoko Matsumura; Sandra Demaria
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

4.  Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells.

Authors:  Manohar C Dange; Nithya Srinivasan; Shyam K More; Sanjay M Bane; Archana Upadhya; Arvind D Ingle; Rajiv P Gude; Rabindranath Mukhopadhyaya; Rajiv D Kalraiya
Journal:  Clin Exp Metastasis       Date:  2014-06-21       Impact factor: 5.150

Review 5.  Microvascular endothelial cell heterogeneity: interactions with leukocytes and tumor cells.

Authors:  P N Belloni; R J Tressler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

6.  Anti-cancer activity of novel dibenzo[b,f]azepine tethered isoxazoline derivatives.

Authors:  Maralinganadoddi Panchegowda Sadashiva; Shivananju NanjundaSwamy; Feng Li; Kanjoormana Aryan Manu; Murugan Sengottuvelan; Doddakunche Shivaramu Prasanna; Nirvanappa Chikkagundagal Anilkumar; Gautam Sethi; Kazuyuki Sugahara; Kanchugarakoppal Subbegowda Rangappa
Journal:  BMC Chem Biol       Date:  2012-10-03

7.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

8.  Physical test for distant metastases in patients with breast cancer.

Authors:  R C Coombes; T J Powles; M Abbott; L De Rivas; H T Ford; V R McCready; A M Neville; J C Gazet
Journal:  J R Soc Med       Date:  1980-09       Impact factor: 5.344

9.  Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.

Authors:  H J Kahn; R Baumal
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.